doxorubicin | Liposomal Vincristine |
& Research News
ASH Paper, 2013: Long Term Results Of a Phase 2
Study Of Vincristine Sulfate Liposome Injection (Marqibo)
Substituted For Non-Liposomal Vincristine In CHOP With Or Without
Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s
agents "can be encapsulated in long-circulating
Stealth liposomes. Liposomes are microscopic vesicles composed of a phospholipid bilayer that are capable of encapsulating active drugs. The Stealth liposomes are formulated with surfacebound methoxypolyethylene glycol, a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system and to increase blood
circulation time. It is hypothesized that liposomal drug molecules are able to penetrate the vasculature of tumours."
Improved outcome when B-cell lymphoma is treated with
combinations of immunoliposomal
anticancer drugs targeted to both the CD19 and CD20 epitopes
Clin Cancer Res. 2004 Apr 1;10(7):2530-7.
Liposomes are microscopic spherical vesicles that
form when phospholipids are hydrated.
Evaluation of Drug Targeting Strategies and
Liposomal Trafficking -
doxorubicin (Doxil™, Caelyx®,
(anthracyclines) can effectively treat aggressive and transformed
lymphoma. However, the use of this chemotherapy agent is limited
by its toxicity, particularly to the heart. A liposome encapsulated
form of the drug called Doxil appears to be safer, and early
indications are encouraging in respect to responses (see below), but
most experts believe that more clinical data and long-term
assessment of side effects are needed before it can be used
routinely as a frontline substitution for doxorubicin. 
doxorubicin (Doxil™) is a unique form of liposomal doxorubicin in
which the liposomes are coated with polyethylene glycol. The
polyethylene glycol confers useful properties including a diminished
uptake by the reticuloendothelial
system, leading to a much longer
half-life in blood (~50-60 hours), and a different toxicity profile
than non-pegylated liposomes. " - cancer.med.umich.edu
hot showers or baths, steam baths or hot tubs 24 before and for 72
hours after treatment with liposomal doxorubicin. This may help
decrease the occurrence of certain skin reactions." - jasper-web.com
Pegylated Liposomal Doxorubicin: Tolerability and Toxicity -
Medscape (free login req.) 02_01_03
Evaluation of Drug Targeting Strategies and
Liposomal Trafficking - bentham.org
Side effects - Cardiac - PAL
Side effect relief - Do's and Don'ts - cancerlynx.com
Full prescribing information from the sponsor - Pdf
Pegylated liposomal doxorubicin as single-agent
treatment of low-grade non-Hodgkin's lymphoma:
a phase II multicenter study. Clin Lymphoma. 2003 Mar;3(4):235-40.
12672273 | Related
Multicenter study of pegylated liposomal doxorubicin in patients
with cutaneous T-cell lymphoma.
Cancer. 2003 Sep 1;98(5):993-1001. PMID:
Pegylated liposomal doxorubicin in combination
chemotherapy in the treatment of previously
diffuse large-B-cell lymphoma.
Med Oncol. 2002;19(1):55-8. PMID: 12025891 - PubMed
Treatment of relapsing or recalcitrant cutaneous
T-cell lymphoma with pegylated liposomal doxorubicin.
J Am Acad
Dermatol. 2000 Jan;42(1 Pt 1):40-6.
PMID: 10607318 - PubMed
Cyclophosphamide, pegylated liposomal doxorubicin
(Caelyx"), vincristine and prednisone (CCOP)
patients with diffuse large B-cell lymphoma: results from a
prospective phase II study.
Haematologica. 2002 Aug;87(8):822-7.
PMID: 12161358 - PubMed
Targeted delivery and triggered release of
liposomal doxorubicin enhances cytotoxicity against
lymphoma cells. Biochim Biophys Acta. 2001 Dec 1;1515(2):144-58.
PMID: 11718670 - PubMed
LIPOSOMAL DOXORUBICIN: A phase I/II trial of liposomal
doxorubicin (TLC D-99, Myocet) with
and prednisone in newly diagnosed aggressive NHL
Year: 2002 Abstract No: 1133
Liposomal encapsulated anthracyclines: new
Curr Oncol Rep. 2001 Mar;3(2):156-62. Review. PMID: 11177748 - PubMed
Liposomal Vincristine (ONCO-TCS™)
- ONCO-TCS - The TCS means transmembrane carrier
systems. It's a drug delivery system that uses a lipid
envelope to encapsulate intravenous chemotherapeutic drugs,
allowing them to circulate in the bloodstream for several hours
after injection and selectively accumulate at a disease site.
It's an investigational therapy being tested currently for
aggressive NHL. Sponsor describes
technology with animation here: INEX
Marqibo Not Eligible For Accelerated Approval, Committee Says
"Inex/Enzon’s liposomal vincristine injection Marqibo
should not be eligible for accelerated approval since there are
other therapies for relapsed non-Hodgkin’s lymphoma, FDA’s
Oncologic Drugs Advisory Committee agreed Dec. 1."
initiates submission of New Drug Application for Onco TCS to the
United States FDA - newswire.ca
Phase I study of
liposomal vincristine. J Clin Oncol. 1999 Feb;17(2):697-705. PMID:
10080616 - PubMed
achieves positive pivotal Phase II/III clinical trial results to
seek FDA marketing approval for Onco TCS (liposomal vincristine)
for relapsed aggressive non-Hodgkin's lymphoma (NHL). - Newswire
in relapsed non-Hodgkin's lymphomas: early results of an ongoing
phase II trial.
Ann Oncol. 2000 Jan;11(1):69-72. PMID: 10690390 - PubMed
TCS: first-line treatment for the aggressive form of NHL Will it
replace the current standard, CHOP + Rituxan?
pharmacology, toxicology and efficacy of sphingomyelin/cholesterol
liposomal vincristine for therapeutic treatment of cancer - springer-ny.com
vincristine in liposomes reduces its toxicity and improves its
anti-tumor efficacy. - liposomes.ubc.ca
LIPOSOMAL VINCRISTINE: A phase II study of liposomal
vincristine in CHOP with rituximab for elderly patients with
untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Year:
2002 Abstract No: 1132